Previous 10 | Next 10 |
2023-08-30 08:35:22 ET More on Abeona Abeona Therapeutics Inc. ( ABEO ) Q2 2023 Earnings Call Transcript Abeona spikes after regulatory update on lead program Abeona expects BLA filing for cell therapy in Q3 as FDA requests more data Abeona stock rises on...
CLEVELAND, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company’s intention to proceed with the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EB-101, its investigational autologous, en...
2023-08-18 13:06:58 ET Gainers: Neptune Wellness Solutions ( NEPT ) +77% . TOP Financial Group ( TOP ) +29% . Hitek Global ( HKIT ) +22% . Agenus ( AGEN ) +19% . ReTo Eco-Solutions ( RETO ) +19% . BK Technol...
2023-08-12 13:42:09 ET Abeona Therapeutics Inc. (ABEO) Q2 2023 Results Conference Call August 08, 2023 08:30 AM ET Company Participants Greg Gin - Vice President of Investor Relations and Corporate Communications Vish Seshadri - Chief Executive Officer Joe Vazzan...
2023-08-08 07:52:20 ET Abeona Therapeutics press release ( NASDAQ: ABEO ): Q2 GAAP EPS of -$0.92 misses by $0.25 . Revenue of $3.5M (+250.0% Y/Y). For further details see: Abeona Therapeutics GAAP EPS of -$0.92 misses by $0.25, revenue of $3.5M
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering in July allow initiation of pre-commercial launch activities for EB-101 Cash on hand plus proceeds from registered direct offering projected ...
2023-07-28 08:26:21 ET More on Abeona Therapeutics Abeona expects BLA filing for cell therapy in Q3 as FDA requests more data Abeona stock rises on new data for rare skin disorder drug EB-101 Abeona Therapeutics files for offering of 15.2M shares by sellers A...
CLEVELAND, July 28, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023....
CLEVELAND, July 19, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it has joined the Rare Disease Company Coalition (RDCC), an alliance of life science companies committed to discovering, developing, and delivering therapies for patients impacted by rare dis...
CLEVELAND, July 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the closing of its previously announced registered direct offering for total gross proceeds of $25 million, before deducting the placement agents’ fees and other offering expenses. “...
News, Short Squeeze, Breakout and More Instantly...
Abeona Therapeutics Inc. Company Name:
ABEO Stock Symbol:
NASDAQ Market:
Abeona Therapeutics Inc. Website:
CLEVELAND and LONDON, July 11, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a cell and gene therapy company with proprietary adeno-associated virus (AAV)-based capsids, and Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, today announced ...
CLEVELAND, July 08, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., and Chief Commercial Officer, Madhav Vasanthavada, Ph.D., M.B.A., will participate in a virtual fireside chat at the Sti...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ABEO on July 3, 2024 06:07AM ET. ABEO was trading at $4.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...